SCHEMBL24029209

SCHEMBL24029209

CCCCCCC(C)CC1CCS(=O)(=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE2 Q9BYF1 1/20 0.39
▸ MAPT P10636 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ADH1B P00325 1/20 0.33
▸ ADH1C P00326 1/20 0.33
▸ ADH1A P07327 1/20 0.33
▸ ADH4 P08319 1/20 0.33
▸ ADH7 P40394 1/20 0.33
▸ PRKD3 O94806 1/20 0.32
▸ PRKCG P05129 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22433073 0.86 TSHR (0.32) ALDH1A1L3MBTL1
SCHEMBL22292462 0.82 LMNA (0.36) GAAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL22500128 0.79 ALDH1A1 (0.47) ACE2MAPTALDH1A1KMT2A
SCHEMBL11677049 0.79 ALDH1A1 (0.47) ACE2MAPTALDH1A1KMT2A
SCHEMBL11677487 0.79 ALDH1A1 (0.47) ACE2MAPTALDH1A1KMT2A
SCHEMBL19038153 0.77 CYP1A2 (0.48) ACE2MAPTALDH1A1KMT2A
SCHEMBL5809132 0.76 GNAO1 (0.47) ACE2MAPTPRKD3PRKCGPRKCB
SCHEMBL23332959 0.76 GNAI3 (0.40) ACE2MAPTALDH1A1KMT2APRKD3
SCHEMBL21859527 0.75 ACE2 (0.39) ACE2MAPTLMNAADH1BADH1C
SCHEMBL23128664 0.74 OPRM1 (0.39) ACE2MAPTALDH1A1KMT2APRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353781-A1 SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING UNITED STATES GOVERNMENT 2021-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353781-A1 SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING CD4, EPCAM, CD2 ACE2 3689/4885MAPT 2795/4885GAA 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback